Screening marine algae metabolites as high-afnity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic

다국어 초록 (Multilingual Abstract)

The recent dissemination of SARS-CoV-2 from Wuhan city to all over the world has created a pandemic. COVID-19 has cost many human lives and created an enormous economic burden. Although many drugs/vaccines are in different stages of clinical trials, still none is clinically available. We have screened a marine seaweed database (1110 compounds) against 3CLpro of SARS-CoV-2 using computational approaches. High throughput virtual screening was performed on compounds, and 86 of them with docking score< −5.000 kcal mol−1 were subjected to standardprecision docking. Based on binding energies (<−6.000 kcal mol−1 ), 9 compounds were further shortlisted and subjected to extra-precision docking. Free energy calculation by Prime-MM/GBSA suggested RC002, GA004, and GA006 as the most potent inhibitors of 3CLpro. An analysis of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of RC002, GA004, and GA006 indicated that only RC002 (callophysin A, from red alga Callophycus oppositifolius) passed Lipinski’s, Veber’s, PAINS and Brenk’s flters and displayed drug-like and lead-like properties.
Analysis of 3CLpro-callophysin A complex revealed the involvement of salt bridge, hydrogen bonds, and hydrophobic interactions. callophysin A interacted with the catalytic residues (His41 and Cys145) of 3CLpro; hence it may act as a mechanism-based competitive inhibitor. Docking energy and docking afnity of callophysin A towards 3CLpro was −8.776 kcal mol−1 and 2.73×106 M−1 , respectively. Molecular dynamics simulation confrmed the stability of the 3CLpro-callophysin A complex. The fndings of this study may serve as the basis for further validation by in vitro and in vivo studies.

참고문헌 (Reference)

1 Cucinotta D, "WHO declares COVID-19 a pandemic" 91 : 157-160, 2020

2 Palese LL, "The structural landscape of SARS-CoV-2 main protease:hints for inhibitor search"

3 Guo YR, "The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19)outbreak-a n update on the status" 7 : 11-, 2020

4 Genheden S, "The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities" 10 : 449-461, 2015

5 Kumar N, "Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of Mycobacterium Tuberculosis" 38 : 3396-3410, 2020

6 Jin Z, "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors" 582 : 289-293, 2020

7 Marques M, "Structure determination of a tetrahydro-?-carboline of arthropod origin : a novel alkaloid-toxin subclass from the Web of SpiderNephila clavipes" 2 : 525-534, 2005

8 Lai CC, "Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and coronavirus disease-2019(COVID-19) : The epidemic and the challenges" 55 : 2-, 2020

9 Friesner RA, "Repasky MP et al(2006)Extra precision glide : docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes" 49 : 6177-6196, 2006

10 Ton AT, "Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds" 2020

11 Oude Munnink BB, "Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands" 2020

12 Madhavi Sastry G, "Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments" 27 : 221-234, 2013

13 Gallimore W, "Pharmacognosy:fundamentals, applications and strategy" Elsevier Inc. 377-400, 2017

14 Brańka AC, "Nosé-Hoover chain method for nonequilibrium molecular dynamics simulation" 61 : 4769-4773, 2000

15 Williams DE, "Nigricanosides A and B, antimitotic glycolipids isolated from the green alga Avrainvillea nigricans collected in Dominica" 129 : 5822-5823, 2007

16 Liang J, "Interaction of the prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: molecular dynamic simulations highlight the stability of the ligand-protein complex" 2020

17 Rehman MT, "Interaction of meropenem with ‘N’ and ‘B’ isoforms of human serum albumin: a spectroscopic and molecular docking study" 34 : 1849-1864, 2016

18 Rehman MT, "Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches" 11 : 1785-1797, 2014

19 Jabir NR, "In silico screening of glycogen synthase kinase-3β targeted ligands against acetylcholinesterase and its probable relevance to Alzheimer’s disease" 2020

20 Halgren TA, "Identifying and characterizing binding sites and assessing druggability" 49 : 377-389, 2009

21 Mittal L, "Identification of potential molecules against COVID-19 main protease through structureguided virtual screening approach" 2020

22 Rodier F, "Hydration of proteinprotein interfaces" 60 : 36-45, 2005

23 Halgren TA, "Glide : a new approach for rapid, accurate docking and scoring. 2. enrichment factors in database screening" 47 : 1750-1759, 2004

24 Song Z, "From SARS to MERS thrusting coronaviruses into the spotlight" 11 : 59-, 2019

25 Chen Y, "Emerging coronaviruses : genome structure, replication, and pathogenesis" 92 : 418-423, 2020

26 Kumar A, "E-pharmacophore modelling, virtual screening, molecular dynamics simulations and in-silico ADME analysis for identification of potential E6 inhibitors against cervical cancer" 1189 : 299-306, 2019

27 Yang H, "Drug design targeting the main protease, the achilles heel of coronaviruses" 12 : 4573-4590, 2006

28 Shen L, "Design, synthesis, and biological evaluation of callophycin A and analogues as potential chemopreventive and anti-cancer agents" 19 : 6182-6195, 2011

29 Zhang L, "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors" 80 (80): 409-412, 2020

30 Anand K, "Coronavirus main proteinase(3CLpro)Structure : basis for design of anti-SARS drugs" 300 : 1763-1767, 2003

31 Martyna GJ, "Constant pressure molecular dynamics algorithms" 101 : 4177-4189, 1994

32 Ovenden SPB, "Callophycin A, a cytotoxic tetrahydro-β-carboline from the red alga Callophycus oppositifolius" 4 : 69-71, 2011

33 Dicky G, "Bioinformation Seaweed metabolite database (SWMD): a database of natural compounds from marine algae"

34 Faheem M, "Biochemical Characterization of CTX-M-15 from Enterobacter cloacae and Designing a Novel Non-β-Lactam-β-Lactamase Inhibitor" 8 : e56926-, 2013

35 Sun H, "Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set" 16 : 16719-16729, 2014

36 Kuntz ID, "A geometric approach to macromolecule-ligand interactions" 161 : 269-288, 1982

37 Daina A, "A BOILED-Egg to predict gastro-intestinal absorption and brain penetration of small molecules" 11 : 1117-1121, 2016

38 She J, "2019 novel coronavirus of pneumonia in Wuhan, China : emerging attack and management strategies" 9 : 1-7, 2020